InvestorsHub Logo

Talon38

07/24/18 12:09 AM

#159129 RE: Doktornolittle #159123

DNL. Good logical comment.

tradeherpete

07/24/18 12:23 AM

#159130 RE: Doktornolittle #159123

Not sure if this helps answer your question,

The company has said it intends to select patients for inclusion into that study based on genomic biomarkers identified in its phase IIa study that chief executive Christopher Missling (pictured) says will enable “enriched clinical trial populations, more robust regulatory submissions and better characterised clinical trial designs.”

http://www.pmlive.com/pharma_news/anavex_sets_up_trial_of_triple-action_alzheimers_drug_1243155